Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma

• Published in: Genes & genomics Vol. 44; no. 4; pp. 445 - 453
• Main Authors: Qiao, Rong, Zhong, Runbo, Liu, Chunlan, Di, Feifei, Zhang, Zheng, Wang, Ling, Xu, Tian, Wang, Yue, Dai, Liping, Gu, Wanjian, Han, Baohui, Yang, Rongxi
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.04.2022; Springer; Springer Nature B.V; 한국유전학회
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Adenocarcinoma; Adenocarcinoma of Lung - pathology; Analysis; Animal Genetics and Genomics; Biomedical and Life Sciences; blood; Cancer; Case-Control Studies; CpG islands; Diagnosis; DNA Methylation; genes; genomics; Human Genetics; Humans; Life Sciences; Lung cancer; lung neoplasms; Lung Neoplasms - pathology; lungs; Mass spectrometry; Mass spectroscopy; Methylation; Microbial Genetics and Genomics; Middle Aged; odds ratio; Peripheral blood; Plant Genetics and Genomics; Promoter Regions, Genetic; quantitative analysis; regression analysis; Research Article; risk; Statistical analysis; 생물학; DNA methylation; Early stage; Biomarker; Lung cancer; SH3BP5
• ISSN: 1976-9571; 2092-9293; 2092-9293
• DOI: 10.1007/s13258-021-01190-0

Background Early detection is essential to improve the survival of lung cancer (LC). The quantitative measurement of specific DNA methylation changes in the peripheral blood could provide an efficient strategy for the detection of early cancer. Objective We applied a candidate approach and assess the association between blood-based SH3BP5 methylation and the risk of lung adenocarcinoma (LUAD) in a case–control cohort. Methods The methylation level of four CpG sites in the promoter of SH3BP5 gene was quantitatively determined by mass spectrometry in 171 very early-stage LUAD patients (93.6% LUAD at stage I) and 190 age and gender-matched controls. The logistic regression and non-parametric tests were used for the statistical analyses. Results We observed a significant association between decreased methylation of SH3BP5_CpG_4 in the peripheral blood and increased risk of LUAD (odds ratio (OR) per-10% methylation = 1.51, P  = 0.006, FDR  = 0.024), and even for the LUAD at stage I (OR per-10% methylation = 1.53, P  = 0.006, FDR  = 0.024). Moreover, the lower quartile of SH3BP5_CpG_4 methylation was correlated with increased risk for LUAD with a P trend of 0.011. Further investigation disclosed that the hypomethylation of SH3BP5_CpG_4 was mostly associated with LUAD in younger subjects (OR per-10% methylation = 2.02, P  = 0.010, age < 55 years old) and probably could be enhanced by advance stage. Conclusion Our study revealed an association between blood-based SH3BP5 hypomethylation and very early-stage LUAD, which provides a novel support for the blood-based methylation signatures as a potential marker for the evaluation of cancer risk.